New Product Enhancement and Four Scientific Presentations to Highlight Cleerly’s Presence at the 75th Annual Scientific Session & Expo of the American College of Cardiology
DENVER–(BUSINESS WIRE)–#AI—Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26). The conference will take place March 28–30, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. ACC.26 convenes clinicians, researchers, and innovators from around the world to advance the science and practice of heart care.
Cleerly will mark the conference with the launch of Cleerly® PREVIEW™, a new workflow-support enhancement designed to assist clinicians with case prioritization and streamline administrative processes, such as prior authorization, for coronary artery disease (CAD) imaging. In addition, Cleerly will present findings from four scientific abstracts spanning plaque quantification, risk stratification, and cardiovascular outcomes, including two studies that draw on data from the CONFIRM2 Registry. CONFIRM2 is a multicenter, international, observational cohort targeting 30,000 patients, with more than 10,750 participants currently enrolled, that aims to perform comprehensive quantification of computed tomography (CT) angiography findings and relate them to clinical variables and cardiovascular clinical outcomes.
Introducing Cleerly PREVIEW
Cleerly PREVIEW is a new workflow-support enhancement to Cleerly’s artificial intelligence-enabled quantitative computed tomography (AI-QCT) platform that helps clinicians prioritize cases based on potential severity of coronary artery disease while also facilitating administrative processes like the prior authorization and reimbursement pathway. Key upgrades include greatest diameter stenosis values and stenosis location information, with stenosis ranges mapped to established reimbursement thresholds.
“Cleerly PREVIEW was built to bring key stenosis data front and center. By connecting this upfront information directly to reimbursement thresholds, we’re helping streamline the administrative workflow and drive efficiency in the prior authorization process,” said James K. Min, founder and CEO of Cleerly.
Conference Schedule
-
Saturday, March 28
- Sex-Based Differences in PREVENT Risk, Coronary Calcium, and Noncalcified Plaque by AI Quantitative Coronary CT (1:18–1:25 PM CST). Session 1036: Subclinical Atherosclerosis in Clinical Practice. Moderated Poster Theater 05, Hall E.
- Meet Cleerly Leadership (3:00–4:00 PM CST). A meet-and-greet at Cleerly’s Booth #1645, offering attendees the opportunity to connect with Cleerly’s executive team. See details below.
-
Sunday, March 29
- AI-Guided Quantitative Coronary CT for Risk Stratification of Major Adverse Cardiovascular Events in Patients with and without Diabetes: CONFIRM 2 Registry (9:42–9:49 AM CST). Session 1082: Intelligence in Action: AI Across the Cardiac Spectrum. Moderated Poster Theater 03, Hall E.
- Advanced Imaging to Understand the Relation between Coronary Microvascular Dysfunction and Coronary Plaque Burden and Vascular Remodeling (12:30–1:30 PM CST). Session 1473: Multimodal Imaging 08. Posters, Hall E. Poster #1473-087.
-
Monday, March 30
- Percent Atheroma Volume by CCTA with AI-QCT Identifies Thresholds for Prognostic Benefit of Revascularization: Insights from the CONFIRM 2 Registry (9:30–10:30 AM CST). Session 1545: Multimodal Imaging 11. Posters, Hall E. Poster #1545-084.
Meet Cleerly Leadership
Join Cleerly on Saturday, March 28, from 3:00–4:00 PM CST at Booth #1645 for a reception with food and beverages, and the opportunity to connect directly with Cleerly’s leadership team.
Stop by Booth #1645 throughout the conference for live demonstrations of Cleerly’s technology, clinical evidence, and discussions with our expert team. A barista will be on-site Saturday and Sunday throughout exhibit hall hours.
To view the full schedule of Cleerly presentations or to schedule a meeting with Cleerly leadership, go to this link.
About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.
Contacts
Cleerly Media Contact
Christy Sievert
[email protected]
